| Obesity |
1 |
1 |
| Fatty Liver |
0 |
0.34 |
| Blood |
0 |
0.32 |
| Medical Innovations |
0 |
0.32 |
| Pandemic |
0 |
0.32 |
| Weight Loss |
0 |
0.32 |
| Gastroenteritis |
0 |
0.27 |
| GLP-1 Receptor Agonist |
0 |
0.27 |
| Liver Disease |
0 |
0.23 |
| Biliary Disease |
0 |
0.2 |
| COVID-19 |
0 |
0.19 |
| Type 2 Diabetes Mellitus |
0 |
0.19 |
| Cancer |
0 |
0.16 |
| Diabetes Mellitus |
0 |
0.16 |
| Diet |
0 |
0.16 |
| Epidemic |
0 |
0.16 |
| Face |
0 |
0.16 |
| Financial Reimbursement |
0 |
0.16 |
| Health Care Economics |
0 |
0.16 |
| Health Education and Counseling |
0 |
0.16 |
| Heart |
0 |
0.16 |
| Hemoglobin A1c |
0 |
0.16 |
| Insurance |
0 |
0.16 |
| Liver |
0 |
0.16 |
| Metabolism |
0 |
0.16 |
| New York |
0 |
0.16 |
| Non-Alcoholic Fatty Liver Disease |
0 |
0.16 |
| Receptors |
0 |
0.16 |
| Steatosis |
0 |
0.16 |
| Stomach |
0 |
0.16 |
| Surgery |
0 |
0.16 |
| Triglycerides |
0 |
0.16 |
| Healthcare and Medical Technology |
0 |
0.1 |
| Metabolic Syndrome |
0 |
0.1 |
| Revenue and Practice Management |
0 |
0.1 |
| Weight Management |
0 |
0.1 |
| Cerebrovascular Accident |
0 |
0.09 |